Payment overview · 2025
General Payments
$755.30
34 reported records · 12 companies
Healthcare provider profile · identity verified
Shahnaz Ahmed, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · BRADENTON, FL · NPI 1780681049
Verified facts
What the public records show
CMS Open Payments records show Shahnaz Ahmed, M.D. received $755.30 in general payments during 2025 across 34 reported records.
AstraZeneca Pharmaceuticals LP accounted for 18.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 24 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga, Jardiance, Mounjaro, Ozempic, Paxlovid, Rybelsus, Trelegy Ellipta.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 59 claims for Farxiga by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 111 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 111 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 130 claims for Mounjaro by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 155 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 189 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 33 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $143.09 | 18.9% | 4 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $114.02 | 15.1% | 5 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $107.89 | 14.3% | 5 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $96.65 | 12.8% | 5 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $48.62 | 6.4% | 3 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $44.86 | 5.9% | 2 | 2025 |
| Daiichi Sankyo Inc. | Unresolved — no canonical attribution shown | $43.26 | 5.7% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $42.88 | 5.7% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $36.43 | 4.8% | 2 | 2025 |
| Philips North America LLC | Unresolved — no canonical attribution shown | $32.76 | 4.3% | 2 | 2025 |
| Alnylam Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $23.98 | 3.2% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $20.86 | 2.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $755.30 | 34 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $143.09 | 4 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $114.02 | 5 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $98.09 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $78.64 | 4 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $78.64 | 4 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $48.62 | 3 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $44.86 | 2 | 2025 |
Source payment records
|
|||||
| INJECTAFER Normalized: injectafer |
Drug | Daiichi Sankyo Inc. | $43.26 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $42.88 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $42.88 | 2 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $42.73 | 2 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $41.01 | 2 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $36.43 | 2 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $34.17 | 2 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $24.04 | 1 | 2025 |
Source payment records
|
|||||
| ONPATTRO Normalized: onpattro |
Drug | Alnylam Pharmaceuticals Inc. | $23.98 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $22.03 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $20.86 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $20.81 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $20.81 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $20.81 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $18.01 | 1 | 2025 |
Source payment records
|
|||||
| Extended Holter Normalized: extended holter |
Device | Philips North America LLC | $17.27 | 1 | 2025 |
Source payment records
|
|||||
| Event Normalized: event |
Device | Philips North America LLC | $15.49 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 189 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 59 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 111 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 130 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 155 | exact normalized | Medicare Part D |
| PAXLOVID paxlovid |
2025 | Paxlovid | 2024 | 33 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 15 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 111 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
59 | 19 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
111 | 21 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
111 | 31 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
130 | 23 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
155 | 31 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
189 | 47 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
33 | 33 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 946 | 241 |
| Atorvastatin Calcium | Atorvastatin Calcium | 921 | 252 |
| Amlodipine Besylate | Amlodipine Besylate | 801 | 230 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 788 | 232 |
| Losartan Potassium | Losartan Potassium | 562 | 156 |
| Ezetimibe | Ezetimibe | 471 | 142 |
| Omeprazole | Omeprazole | 389 | 121 |
| Lisinopril | Lisinopril | 371 | 112 |
| Alprazolam | Alprazolam | 344 | 82 |
| Metformin Hcl | Metformin Hcl | 319 | 88 |
| Metoprolol Tartrate | Metoprolol Tartrate | 314 | 85 |
| Gabapentin | Gabapentin | 312 | 98 |
| Pantoprazole Sodium | Pantoprazole Sodium | 276 | 91 |
| Hydrochlorothiazide | Hydrochlorothiazide | 262 | 80 |
| Escitalopram Oxalate | Escitalopram Oxalate | 261 | 80 |
| Valsartan | Valsartan | 250 | 73 |
| Metoprolol Succinate | Metoprolol Succinate | 236 | 72 |
| Potassium Chloride | Potassium Chloride | 225 | 67 |
| Simvastatin | Simvastatin | 212 | 61 |
| Fluticasone Propionate | Fluticasone Propionate | 209 | 79 |
| Meloxicam | Meloxicam | 203 | 73 |
| Eliquis | Apixaban | 189 | 47 |
| Famotidine | Famotidine | 175 | 66 |
| Furosemide | Furosemide | 172 | 61 |
| Citalopram Hbr | Citalopram Hydrobromide | 171 | 48 |
| Tramadol Hcl | Tramadol Hcl | 165 | 52 |
| Atenolol | Atenolol | 158 | 47 |
| Tamsulosin Hcl | Tamsulosin Hcl | 158 | 50 |
| Ozempic | Semaglutide | 155 | 31 |
| Montelukast Sodium | Montelukast Sodium | 150 | 52 |
| Trazodone Hcl | Trazodone Hcl | 145 | 47 |
| Alendronate Sodium | Alendronate Sodium | 142 | 48 |
| Allopurinol | Allopurinol | 140 | 40 |
| Clopidogrel | Clopidogrel Bisulfate | 140 | 44 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 130 | 44 |
| Mounjaro | Tirzepatide | 130 | 23 |
| Sertraline Hcl | Sertraline Hcl | 126 | 36 |
| Carvedilol | Carvedilol | 122 | 33 |
| Duloxetine Hcl | Duloxetine Hcl | 119 | 36 |
| Pravastatin Sodium | Pravastatin Sodium | 116 | 31 |
| Glimepiride | Glimepiride | 113 | 36 |
| Zolpidem Tartrate | Zolpidem Tartrate | 112 | 26 |
| Jardiance | Empagliflozin | 111 | 31 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 111 | 21 |
| Prednisone | Prednisone | 103 | 60 |
| Bupropion Xl | Bupropion Hcl | 101 | 28 |
| Hydralazine Hcl | Hydralazine Hcl | 100 | 33 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 95 | 28 |
| Fluoxetine Hcl | Fluoxetine Hcl | 93 | 31 |
| Synthroid | Levothyroxine Sodium | 87 | 21 |
| Clonazepam | Clonazepam | 83 | 11 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 75 | 23 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 74 | 23 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 69 | 29 |
| Lovastatin | Lovastatin | 69 | 16 |
| Tizanidine Hcl | Tizanidine Hcl | 66 | 20 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 65 | 56 |
| Methylprednisolone | Methylprednisolone | 61 | 56 |
| Paroxetine Hcl | Paroxetine Hcl | 61 | 14 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 61 | 20 |
| Repatha Syringe | Evolocumab | 60 | 14 |
| Azithromycin | Azithromycin | 59 | 45 |
| Farxiga | Dapagliflozin Propanediol | 59 | 19 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 56 | 16 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 54 | 15 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 54 | 16 |
| Myrbetriq | Mirabegron | 51 | 14 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 50 | 18 |
| Estradiol | Estradiol | 50 | 17 |
| Metformin Hcl Er | Metformin Hcl | 50 | 17 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 50 | suppressed |
| Mirtazapine | Mirtazapine | 49 | 20 |
| Memantine Hcl | Memantine Hcl | 48 | 11 |
| Armour Thyroid | Thyroid,pork | 47 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 47 | 16 |
| Repatha Sureclick | Evolocumab | 47 | 12 |
| Donepezil Hcl | Donepezil Hcl | 46 | 14 |
| Pregabalin | Pregabalin | 45 | 15 |
| Spironolactone | Spironolactone | 45 | 14 |
| Doxycycline Hyclate | Doxycycline Hyclate | 44 | 35 |
| Amitriptyline Hcl | Amitriptyline Hcl | 43 | 13 |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 42 | 14 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 42 | 30 |
| Cephalexin | Cephalexin | 41 | 24 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 41 | 12 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 41 | 13 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 41 | 26 |
| Lorazepam | Lorazepam | 40 | 16 |
| Valacyclovir | Valacyclovir Hcl | 40 | 19 |
| Fenofibrate | Fenofibrate Nanocrystallized | 38 | 12 |
| Xarelto | Rivaroxaban | 38 | 13 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 36 | 15 |
| Tresiba Flextouch U-100 | Insulin Degludec | 36 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 35 | 12 |
| Fenofibrate | Fenofibrate | 35 | 11 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 35 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 35 | suppressed |
| Fluconazole | Fluconazole | 34 | 14 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 33 | 31 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 33 | 26 |
| Diclofenac Sodium | Diclofenac Sodium | 33 | 16 |
| Paxlovid | Nirmatrelvir/Ritonavir | 33 | 33 |
| Ibuprofen | Ibuprofen | 31 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 30 | 11 |
| Topiramate | Topiramate | 30 | suppressed |
| Celecoxib | Celecoxib | 29 | 12 |
| Meclizine Hcl | Meclizine Hcl | 29 | 15 |
| Ondansetron Hcl | Ondansetron Hcl | 29 | 18 |
| Rizatriptan | Rizatriptan Benzoate | 29 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 29 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 28 | 26 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 28 | suppressed |
| Cefdinir | Cefdinir | 27 | 25 |
| Gemfibrozil | Gemfibrozil | 27 | suppressed |
| Nystatin | Nystatin | 27 | 20 |
| Bumetanide | Bumetanide | 26 | suppressed |
| Chlorthalidone | Chlorthalidone | 26 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 24 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 24 | suppressed |
| Methocarbamol | Methocarbamol | 24 | 17 |
| Amiodarone Hcl | Amiodarone Hcl | 23 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 23 | suppressed |
| Sucralfate | Sucralfate | 23 | suppressed |
| Amoxicillin | Amoxicillin | 22 | 22 |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 22 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 21 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 21 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 21 | suppressed |
| Mupirocin | Mupirocin | 21 | 19 |
| Tradjenta | Linagliptin | 21 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 20 | suppressed |
| Hydrocortisone | Hydrocortisone | 20 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 20 | suppressed |
| Januvia | Sitagliptin Phosphate | 20 | suppressed |
| Lagevrio (Eua) | Molnupiravir | 20 | 19 |
| Nitroglycerin | Nitroglycerin | 20 | 11 |
| Ropinirole Hcl | Ropinirole Hcl | 20 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 19 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 19 | suppressed |
| Diazepam | Diazepam | 19 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 19 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 19 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 19 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 18 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 18 | suppressed |
| Lidocaine | Lidocaine | 17 | suppressed |
| Temazepam | Temazepam | 17 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 16 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 16 | suppressed |
| Folic Acid | Folic Acid | 16 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 16 | suppressed |
| Lansoprazole | Lansoprazole | 16 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 16 | suppressed |
| Ondansetron Odt | Ondansetron | 16 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 16 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 16 | suppressed |
| Lamotrigine | Lamotrigine | 15 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 15 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 15 | suppressed |
| Rybelsus | Semaglutide | 15 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 14 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 14 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 14 | 13 |
| Telmisartan-Hydrochlorothiazid | Telmisartan/Hydrochlorothiazid | 14 | suppressed |
| Dutasteride | Dutasteride | 13 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 13 | suppressed |
| Naltrexone Hcl | Naltrexone Hcl | 13 | suppressed |
| Naproxen | Naproxen | 13 | suppressed |
| Nifedipine Er | Nifedipine | 13 | suppressed |
| Novolin R | Insulin Regular, Human | 13 | suppressed |
| Pilocarpine Hcl | Pilocarpine Hcl | 13 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 13 | suppressed |
| Chlordiazepoxide-Amitriptyline | Amitriptyline/Chlordiazepoxide | 12 | suppressed |
| Glipizide | Glipizide | 12 | suppressed |
| Irbesartan | Irbesartan | 12 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 12 | suppressed |
| Novolin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 12 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 12 | suppressed |
| Budesonide Dr | Budesonide | 11 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 11 | suppressed |
| Finasteride | Finasteride | 11 | suppressed |
| Lactulose | Lactulose | 11 | suppressed |
| Novolog Flexpen | Insulin Aspart | 11 | suppressed |
| Telmisartan | Telmisartan | 11 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 11 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $755.30 · 34 records | AstraZeneca Pharmaceuticals LP | ABRYSVO, AIRSUPRA, COMIRNATY, Cologuard Collection Kit, ELIQUIS, Event, Extended Holter, FARXIGA, FREESTYLE LIBRE 3, INJECTAFER, JARDIANCE, LEQVIO, MOUNJARO, NURTEC ODT, ONPATTRO, OTEZLA, Ozempic, PAXLOVID, PREVNAR 20, REPATHA, Rybelsus, TRELEGY ELLIPTA, ZAVZPRET, ZEPBOUND | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error